Menu
  • Nanoparticle In Vivo Transfection Reagent
  • Astrocyte
  • Kidney In Vivo Transfection
  • Pegylated Liposome

Shop Products

Category Archives: Xenograft

Preclinical Research with Advanced Oncology Models and Immunooncology Services by Altogen Labs

Altogen Labs is a preclinical research organization specializing in the testing and evaluation of novel pharmacological and biological treatments, including novel anticancer therapies, medical compounds, vaccines, cosmetics, and a wide array of natural products and extracts. With a dedicated team of scientists, Altogen Labs provides a comprehensive suite of laboratory services, utilizing the latest technologies and methodologies to drive progress in oncology and accelerate drug development. The company offers specialized immuno-oncology services, utilizing advanced humanized and immunodeficient rodent models, including models engrafted with peripheral blood mononuclear cells (PBMC), CD34+ hematopoietic stem cells, and induced pluripotent stem cells (iPSC). These cutting-edge models provide robust platforms for evaluating immune responses, drug efficacy, and toxicity.

With a strong focus on drug discovery and development in oncology, Altogen Labs accelerates the progress of novel therapies by offering over 100 in-house validated xenograft models, including conventional CDX, patient-derived xenografts (PDX), in vitro patient-derived cell cultures (PDC), and patient-derived organoids (PDOrg). One of Altogen Labs’ key strengths is its platform, which allows for the prediction of drug efficacy in genetically characterized, clinically relevant cancer models. This approach, combined with in vivo testing of new cancer therapies in humanized models, delivers the best possible preclinical data.

Altogen’s team conducts extensive toxicity studies (acute, sub-chronic, and chronic) to evaluate compound safety and toxic effects over time. Acute studies focus on short-term impacts, while sub-chronic and chronic studies assess toxicity over months to a year. These comprehensive analyses ensure the safety of potential drug candidates. Understanding potential adverse effects is essential for ensuring clinical efficacy and safety. In vivo efficacy and safety studies utilizing various xenograft models explore different dosage levels and drug administration routes to optimize delivery and biodistribution for investigational new drugs (INDs).

Read more about Altogen Labs immunooncology services

About Altogen Labs
Altogen Labs’ research facility is located in Austin, Texas, and provides a broad range of preclinical and biological CRO services for safety and efficacy studies, supporting early-stage drug discovery and the development of novel therapies. Altogen Labs is a reliable partner for all preclinical research needs. With cutting-edge technologies, an experienced team of scientists, and a commitment to excellence, the company continues to drive innovation in the fields of oncology and immunotherapy.

Contact
Altogen Labs
11200 Menchaca Rd
Austin TX 78748
info@altogenlabs.com

Validated Breast Cancer Xenograft Models

Altogen Labs is a GLP-compliant biotech laboratory that specializes in oncology research studies and provides preclinical testing of new medicines that often require a sequence of experiments utilizing various scientific methods to demonstrate novel compound anti-cancer efficacy, safety, and mechanism of action. Breast cancer is the second leading cancer that causes death in women globally,… Continue Reading

Crossing Blood-Brain Barrier and In Vivo Delivery of Negatively Charged Biomolecules into Glioblastoma Enabled by Altogen's Nanoparticle In Vivo Transfection Reagent

LAS VEGAS, NEVADA – July 19, 2021 – Altogen Biosystems, leading manufacturer of in vivo transfection products, announced today that Altogen’s nanoparticle-based in vivoTransfection reagent (catalog #5031) was demonstrated to be effective for glioblastoma-targeted co-delivery of plasmid DNA (3.7 kb) and chemically modified siRNA. This transfection reagent was used in over 30 research publications, demonstrating highly… Continue Reading

Nanoparticle In Vivo Transfection Reagent (Altogen)

July 27, 2021 – Altogen Biosystems® is a biotechnology manufacturing company that specializes in the development and testing of optimized cell transfection reagents and kits for both in vitro and in vivo delivery. In 2018 Altogen Biosystems launched the AltoFect transfection reagent formulated for difficult-to-transfect cells (like B-cells, T-cells), and primary cell cultures that are… Continue Reading

cGMP-grade Nanoparticle Transfection Reagent for In Vivo Delivery

Altogen Biosystems is a manufacturer of life science research products that includes in vivo transfection reagents designed for tissue-targeted delivery of biomolecules. Altogen’s Nanoparticle In Vivo Transfection Reagent was launched in 2008 and used in over 30 research publications demonstrating highly efficient delivery of cargo nucleic acids (siRNA, microRNA, mRNA, plasmid DNA, and small proteins)… Continue Reading